Response of mucocutaneous lesions to rituximab in a case of melanoma differentiation antigen 5-related dermatomyositis

Dermatology. 2012;225(4):376-80. doi: 10.1159/000346573. Epub 2013 Feb 15.

Abstract

We report the first case in Western Europe of a person presenting with dermatomyositis associated with melanoma differentiation antigen 5 antibodies. She sequentially developed severe mucocutaneous erythematous and itchy lesions of the face, scalp, neck, knees and recurrent aphthae. In addition she presented painful, periungual, edematous digital lesions and small ulcers with digital necrosis. Her rapidly evolving, near-fatal interstitial lung disease responded to high-dose intravenous cyclophosphamide. However, her recurrent mucocutaneous manifestations improved only after rituximab administration.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Autoantibodies / blood*
  • DEAD-box RNA Helicases / immunology*
  • Dermatomyositis / drug therapy*
  • Dermatomyositis / immunology
  • Dermatomyositis / pathology
  • Female
  • Humans
  • Interferon-Induced Helicase, IFIH1
  • Rituximab
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Autoantibodies
  • Rituximab
  • IFIH1 protein, human
  • DEAD-box RNA Helicases
  • Interferon-Induced Helicase, IFIH1